Trending...
- Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
- Suburban Orthopaedics Expands Comprehensive Orthopaedic Care in Northwest Suburbs
- Over 98% of crypto owners globally don't declare taxes, new report find
~ Chicago, IL - Abbott (NYSE: ABT) has released groundbreaking data from its TRILUMINATE™ Pivotal trial, showcasing the significant and sustained benefits of its TriClip™ transcatheter edge-to-edge repair (TEER) system in treating tricuspid regurgitation (TR), also known as a leaky heart valve. The results, presented at the American College of Cardiology's Annual Scientific Session (ACC.25), demonstrate that the TriClip device offers substantial improvements in TR severity after two years, as well as a reduction in hospitalizations due to heart failure and long-term quality-of-life benefits for patients.
TR occurs when the tricuspid valve, which controls blood flow between the right atrium and right ventricle of the heart, does not close properly. This can lead to a decrease in blood flow and force the heart to work harder, causing symptoms such as fatigue and shortness of breath. If left untreated, TR can lead to serious complications such as atrial fibrillation, heart failure, and even death. For patients who are not suitable candidates for surgery and continue to experience symptoms or persistent TR despite medical therapy, the TriClip offers a much-needed option that can improve their quality of life and reduce hospitalizations.
More on illi News
The data from the TRILUMINATE Pivotal study showed that after two years, the TriClip continued to demonstrate superiority over medical therapy while meeting secondary endpoints such as recurrent hospitalizations due to heart failure and freedom from all-cause mortality. Additionally, there was a significant reduction in TR grade among patients who received the device compared to those who received medical therapy alone. After one year of the trial, patients in the control group were allowed to cross over and receive TriClip therapy, with more than half opting for this treatment.
Other positive findings from the study include a significant decrease in hospitalizations due to heart failure among patients who received TriClip compared to those who received medical therapy alone. This trend continued even among patients who crossed over to receive TriClip after the first year of the trial. There was also a sustained improvement in quality of life among patients who received TriClip, with an average increase of 15 points on the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, which measures social abilities, symptoms, and overall quality of life. Patients who crossed over to receive TriClip also experienced similar improvements in their KCCQ score.
More on illi News
Dr. Saibal Kar, from Los Robles Regional Medical Center in Thousand Oaks, California, commented on the significance of these findings: "With the TRILUMINATE Pivotal two-year results, tricuspid transcatheter edge-to-edge repair with the TriClip device for severe, symptomatic tricuspid regurgitation reduced heart failure hospitalizations compared to the control group. Improvements in tricuspid regurgitation severity and quality of life were sustained through two years." He added that these results highlight the safety and effectiveness of TriClip as a sustainable way to repair the tricuspid valve.
Sandra Lesenfants, senior vice president of Abbott's structural heart business, emphasized the importance of these findings for patients with TR: "These new data reinforce the critical role TriClip plays in helping people with tricuspid regurgitation live the life they want while reducing the risk of hospitalization." She also noted that many patients with TR face serious challenges and limited treatment options prior to the approval of TriClip.
In conclusion, Abbott's TRILUMINATE Pivotal trial has shown that its TriClip transcatheter edge-to-edge repair system offers significant and sustained benefits for patients with severe tricuspid regurgitation. With its ability to reduce hospitalizations due to heart failure and improve quality of life for patients, this device represents a major advancement in the treatment of TR and offers hope for those who were previously limited in their options.
TR occurs when the tricuspid valve, which controls blood flow between the right atrium and right ventricle of the heart, does not close properly. This can lead to a decrease in blood flow and force the heart to work harder, causing symptoms such as fatigue and shortness of breath. If left untreated, TR can lead to serious complications such as atrial fibrillation, heart failure, and even death. For patients who are not suitable candidates for surgery and continue to experience symptoms or persistent TR despite medical therapy, the TriClip offers a much-needed option that can improve their quality of life and reduce hospitalizations.
More on illi News
- Chicago: Mayor Brandon Johnson, Department of Housing Announce $300 Million Investment in Affordable Housing
- Mesa West Capital Funds $81 Million Loan to Refinance 313-Unit Multifamily Community in Houston
- Indies United is pleased to present our April 2026 book releases
- Century Fasteners Corp. Exhibiting at 2026 MRO Americas Show – April 21-23, 2026 – Booth #2257
- Digi 995 Launches Robot Head Corduroy Cap in Premium Vintage Style
The data from the TRILUMINATE Pivotal study showed that after two years, the TriClip continued to demonstrate superiority over medical therapy while meeting secondary endpoints such as recurrent hospitalizations due to heart failure and freedom from all-cause mortality. Additionally, there was a significant reduction in TR grade among patients who received the device compared to those who received medical therapy alone. After one year of the trial, patients in the control group were allowed to cross over and receive TriClip therapy, with more than half opting for this treatment.
Other positive findings from the study include a significant decrease in hospitalizations due to heart failure among patients who received TriClip compared to those who received medical therapy alone. This trend continued even among patients who crossed over to receive TriClip after the first year of the trial. There was also a sustained improvement in quality of life among patients who received TriClip, with an average increase of 15 points on the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, which measures social abilities, symptoms, and overall quality of life. Patients who crossed over to receive TriClip also experienced similar improvements in their KCCQ score.
More on illi News
- Blue Sparrow Coffee named Best Matcha in Westword's Best of Denver 2026
- Ocean County College Introduces Pathways to Simplify the Student Journey and Strengthen Career Connections
- Kiko Nation Expands to Apple App Store, Achieving Full Mobile Deployment for Livestock Digital Registry Platform
- The Lawyers' Marketer Launches Claude AI Implementation Service for Law Firms
- Certified Trading Card Association and Collectors MD Launch Healthy Hobby Initiative
Dr. Saibal Kar, from Los Robles Regional Medical Center in Thousand Oaks, California, commented on the significance of these findings: "With the TRILUMINATE Pivotal two-year results, tricuspid transcatheter edge-to-edge repair with the TriClip device for severe, symptomatic tricuspid regurgitation reduced heart failure hospitalizations compared to the control group. Improvements in tricuspid regurgitation severity and quality of life were sustained through two years." He added that these results highlight the safety and effectiveness of TriClip as a sustainable way to repair the tricuspid valve.
Sandra Lesenfants, senior vice president of Abbott's structural heart business, emphasized the importance of these findings for patients with TR: "These new data reinforce the critical role TriClip plays in helping people with tricuspid regurgitation live the life they want while reducing the risk of hospitalization." She also noted that many patients with TR face serious challenges and limited treatment options prior to the approval of TriClip.
In conclusion, Abbott's TRILUMINATE Pivotal trial has shown that its TriClip transcatheter edge-to-edge repair system offers significant and sustained benefits for patients with severe tricuspid regurgitation. With its ability to reduce hospitalizations due to heart failure and improve quality of life for patients, this device represents a major advancement in the treatment of TR and offers hope for those who were previously limited in their options.
Filed Under: Business
0 Comments
Latest on illi News
- PandaGuarantee Launches Rent Guarantor Service in New York City
- The $112M Marketing Lesson Joe Whyte Learned: Why 'More Traffic' Is the Biggest Lie in Digital Marketing
- Daniel Kaufman Expands Kaufman & Company Real Estate Platform With New Acquisitions, AI-Driven Industrial Development and Nationwide Growth Initiative
- purelyIV Launches Lab Testing Services in Metro Detroit
- Chicago: ICYMI: Mayor Brandon Johnson's ICE Playbook Spreads as Cities Challenge Trump's Crackdown
- On the 296th Anniversary of the Ceremony That Made His Ancestor Emperor, a Cherokee Descendant Publishes the Novel That Restores Him
- Mayor Brandon Johnson, DFSS, My Chi. My Future., Host Fifth Annual Teen Bash at Navy Pier, Empowering Young Chicagoans
- The City of Naperville Launches 2026 National Community Survey
- NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
- DC Accounting Firm Offers Free Business CRM to Small Business Clients Alongside Weekly Bookkeeping Model
- CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
- Explosive $10 Billion Counter-Drone Market with AI-Powered Defense Ecosystem: ZenaTech, Inc. (N A S D A Q: ZENA)
- High-Value Execution Phase Begins: Bitcoin Bancorp Ignites Texas Rollout of Digital Asset ATM Network: Bitcoin Bancorp (Stock Symbol: BCBC) $BCBC
- Upgrade Kitchen Performance with SMEG Parts at HnK Parts for Ovens & Fridges
- PIXALPHA STUDIO Launches as Chicago's Premier Custom Web Design Agency
- UK Financial Ltd Tokenized LTNS 1, A $1.1 T Asset-Backed ERC-3643 Security Token with 11 On-Chain Contracts Verifying, Compliant Real-World Value
- SelfCare is now HealthCare across America
- How a Former Fast Food Joint Became Peoria's Favorite Taproom - The Story behind Bust'd Brewing
- Isringhausen Team Member Recognized at 2026 DSI Awards
- Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets